LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

Home・Akciju saraksts・Supernus Pharmaceuticals Inc

Supernus Pharmaceuticals Inc

Slēgts

SektorsVeselības aprūpe

54.41 -1.91

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

53.47

Max

54.77

Galvenie mērījumi
By Trading Economics
Ienākumi	-68M -45M
Pārdošana	27M 192M
P/E Sektora vidējais	48.435 108.767
Peļņas marža	-23.486
Darbinieki	674
EBITDA	-75M -37M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+13.59% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 5. maijs

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-217M 2.9B
Iepriekšējā atvēršanas cena	56.32
Iepriekšējā slēgšanas cena	54.41

Ziņu noskaņojums

By Acuity

45%

55%

136 / 352 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Weak Bearish Evidence

31.35 / 32.36 Atbalsts un pretestība

Supernus Pharmaceuticals Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 1. marts 23:35 UTC

Galvenie ziņu notikumi

Oil Prices Jump in Asia as U.S.-Iran Conflict Stokes Supply Fears -- Energy Comment

2026. g. 1. marts 23:49 UTC

Tirgus saruna

Galvenie ziņu notikumi

Australian Gold-Mining Stocks Rally as Attack on Iran Drives Gold Higher -- Market Talk

2026. g. 1. marts 23:47 UTC

Tirgus saruna

Galvenie ziņu notikumi

Gold, Silver Rise as Middle East Conflict Spurs Safe-Haven Demand -- Market Talk

2026. g. 1. marts 23:41 UTC

Tirgus saruna

Galvenie ziņu notikumi

Lasting Oil Price Shock Could Stoke Global Inflation -- Market Talk

2026. g. 1. marts 23:39 UTC

Tirgus saruna

Galvenie ziņu notikumi

Global Equities Roundup: Market Talk

2026. g. 1. marts 23:39 UTC

Tirgus saruna

Galvenie ziņu notikumi

Nikkei May Fall Amid Concerns About Higher Energy Prices -- Market Talk

2026. g. 1. marts 23:36 UTC

Tirgus saruna

Galvenie ziņu notikumi

Oil Jumps as Middle East Conflict Heightens Supply Disruption Concerns -- Market Talk

2026. g. 1. marts 23:24 UTC

Tirgus saruna

Global Energy Roundup: Market Talk

2026. g. 1. marts 23:24 UTC

Tirgus saruna

Financial Markets Trim Bets on RBA Hike in May -- Market Talk

2026. g. 1. marts 23:21 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 1. marts 23:21 UTC

Tirgus saruna

Sky Network TV's Risk/Reward Still Not Attractive -- Market Talk

2026. g. 1. marts 23:19 UTC

Galvenie ziņu notikumi

Front-Month Brent Crude Oil Futures Rose 8.5% to $79.08/bbl

2026. g. 1. marts 23:17 UTC

Galvenie ziņu notikumi

Front-Month WTI Crude Oil Futures Rose 8.4% to $72.65/bbl

2026. g. 1. marts 23:14 UTC

Galvenie ziņu notikumi

Front-Month WTI Crude Oil Futures Extend Gains in Early Trade

2026. g. 1. marts 22:55 UTC

Galvenie ziņu notikumi

Spot Gold Rises 1.9% to $5,278.61/oz Amid Middle East Conflict

2026. g. 1. marts 22:54 UTC

Galvenie ziņu notikumi

Front-Month WTI Crude Oil Futures Rise Amid Middle East Conflict

2026. g. 1. marts 22:53 UTC

Galvenie ziņu notikumi

Front-Month WTI Crude Oil Futures Rise 3.2% to $67.29/bbl

2026. g. 1. marts 22:38 UTC

Tirgus saruna

Galvenie ziņu notikumi

Attack on Iran Likely to Push Up Floor Under Gold -- Market Talk

2026. g. 1. marts 22:21 UTC

Peļņas

Berkshire's Earnings Weren't as Bad as They Looked. A Goodwill Write-Down Hit Operating Profits. -- Barrons.com

2026. g. 1. marts 22:17 UTC

Tirgus saruna

Financial Markets Trim Bets On RBA Hike In May -- Market Talk

2026. g. 1. marts 22:13 UTC

Tirgus saruna

Galvenie ziņu notikumi

OPEC+ Oil Output Boost Could Be Moot if Strait of Hormuz Unavailable -- Market Talk

2026. g. 1. marts 22:00 UTC

Tirgus saruna

Galvenie ziņu notikumi

Oil Could Surge Above $100 If Flows Don't Return to Normal Quickly -- Market Talk

2026. g. 1. marts 21:40 UTC

Tirgus saruna

Galvenie ziņu notikumi

Spot Gold Up as Investors Shield Against Risk -- Market Talk

2026. g. 1. marts 21:35 UTC

Tirgus saruna

Galvenie ziņu notikumi

Oil Prices Seen Rising to Low to Mid-US$80s Per Barrel -- Market Talk

2026. g. 1. marts 21:30 UTC

Tirgus saruna

Australian Dollar Weakens Most as Trader Fear Long-Term Conflict -- Market Talk

2026. g. 1. marts 21:27 UTC

Tirgus saruna

Galvenie ziņu notikumi

Oil Prices Likely to Rise on Iran Conflict But to Manageable Levels -- Market Talk

2026. g. 1. marts 21:19 UTC

Tirgus saruna

Galvenie ziņu notikumi

Shipping Disruptions 'More Acute Risk' Than Oil Output From Iran Conflict -- Market Talk

2026. g. 1. marts 20:58 UTC

Tirgus saruna

Galvenie ziņu notikumi

Risk Off Stance in Markets Amid Fears of Wider Conflict -- Market Talk

2026. g. 1. marts 20:40 UTC

Tirgus saruna

Australia Dollar to Fall Sharply Against U.S. Dollar on Middle East Conflict -- Market Talk

2026. g. 1. marts 20:24 UTC

Tirgus saruna

Galvenie ziņu notikumi

Brent Crude at $100/bbl Could Slow Pace of Global Rate Cuts -- Market Talk

Salīdzinājums

Cenas izmaiņa

Supernus Pharmaceuticals Inc Prognoze

Cenas mērķis

By TipRanks

13.59% augšup

Prognoze 12 mēnešiem

Vidējais 62.17 USD 13.59%

Augstākais 65 USD

Zemākais 55 USD

Pamatojoties uz 6 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Supernus Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

6 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 6 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Supernus Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

31.35 / 32.36Atbalsts un pretestība

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Noskaņojums

By Acuity

136 / 352 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Supernus Pharmaceuticals Inc

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.